Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
15.35
-0.79 (-4.87%)
Apr 1, 2025, 3:45 PM EDT - Market open
Spyre Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
65
Market Cap
924.95M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
SYRE News
- 4 days ago - Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody - PRNewsWire
- 24 days ago - Spyre Therapeutics Announces Grants of Inducement Awards - PRNewsWire
- 4 weeks ago - Spyre Therapeutics: Targeting The Future Of IBD Treatment - Seeking Alpha
- 4 weeks ago - Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 5 weeks ago - Spyre Therapeutics to Participate in Upcoming March Investor Conferences - PRNewsWire
- 5 weeks ago - Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation - PRNewsWire
- 2 months ago - Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts - PRNewsWire
- 3 months ago - Spyre Therapeutics Added to the Nasdaq Biotechnology Index - PRNewsWire